KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Current Leases (2019 - 2025)

Twist Bioscience (TWST) has disclosed Current Leases for 7 consecutive years, with $12.2 million as the latest value for Q4 2025.

  • Quarterly Current Leases fell 18.55% to $12.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $12.2 million through Dec 2025, down 18.55% year-over-year, with the annual reading at $13.8 million for FY2025, 6.64% down from the prior year.
  • Current Leases for Q4 2025 was $12.2 million at Twist Bioscience, down from $13.8 million in the prior quarter.
  • The five-year high for Current Leases was $15.5 million in Q2 2025, with the low at $6.5 million in Q1 2021.
  • Average Current Leases over 5 years is $13.2 million, with a median of $14.2 million recorded in 2022.
  • The sharpest move saw Current Leases surged 117.47% in 2022, then decreased 18.55% in 2025.
  • Over 5 years, Current Leases stood at $12.7 million in 2021, then rose by 12.16% to $14.2 million in 2022, then rose by 4.08% to $14.8 million in 2023, then grew by 1.5% to $15.0 million in 2024, then decreased by 18.55% to $12.2 million in 2025.
  • According to Business Quant data, Current Leases over the past three periods came in at $12.2 million, $13.8 million, and $15.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.